Alvotech Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY Revenue (est.)
$655.8Mnext fiscal year
FY EPS (est.)
$0.01next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results (First Nine Months) | 11 Nov 2026 |
| Q4 2026 & Full-Year 2026 Financial Results | 10 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Total Revenues Annually593MTarget: 650000000 - 700000000
Adjusted EBITDA Annually137MTarget: 180000000 - 220000000
Watch Items
- FDA BLA Resubmissions for AVT05 and AVT06Trigger: FDA regulatory review outcome expected by late 2026Action: Monitor FDA inspection status of the Reykjavik facility and subsequent regulatory decisions.
- Cash Runway and Cash Flow RecoveryTrigger: Targeting positive cash flow in Q4 2026Action: Track quarterly cash burn rates and the execution of the newly raised capital from the June 2026 share offering.
Research as of 20 Jun 2026